Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 09, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in beneficial interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. R Bondy. On January 06, 2006, he purchased 1 Ordinary Share under a Personal Equity Plan at a price of GBP 14.836.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the director's transaction.
Investor Verification Points
- Verify the identity of Mr. R Bondy and his role within GlaxoSmithKline plc.
- Confirm the share price of GBP 14.836 against market data for January 06, 2006.
- Note that this filing does not reflect the company's overall financial health or operational results.